Plain-English translation of NCT05093374 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether using advanced computer software to measure fluid in the eye can help doctors make better decisions about when to give eye injections for wet macular degeneration. You'll receive monthly injections of a medication like Ranibizumab, Aflibercept, or Brolucizumab — drugs that are already used to treat this condition. The study compares two approaches: one that uses precise fluid measurements from AI to guide treatment decisions, and another that uses traditional visual checks.
Wet macular degeneration requires ongoing injections to prevent vision loss, but each injection carries small risks and costs. Doctors want to give patients only the injections they truly need — not too few (which could hurt vision) and not too many (which could be unnecessary). This study tests whether AI-powered fluid measurement can help doctors get this balance just right for each patient.
You likely qualify if…
You likely don't qualify if…
You'll visit the clinic monthly for 12 months. At each visit, you'll have your eye scanned with advanced imaging (OCT), and the scan will be analyzed by computer software to measure fluid in your eye. Based on these measurements and your eye doctor's judgment, you may receive an injection into the eye. The study compares whether this AI-guided approach is better than traditional methods at keeping your vision stable while minimizing unnecessary injections.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Austria
Phase
Post-approval monitoring
Sponsor
Medical University of Vienna
Enrollment target
~290 participants
Started
March 2021
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
50 Years – 100 Years
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Stefan Sacu, MD
Medical University of Vienna, Dept. of Ophthalmology and Optometry
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.